Seminars in Pediatric Neurology
Volume 13, Issue 1 , Pages 37-42 , March 2006

The Neurobiology of Tuberous Sclerosis Complex

  • Kevin C. Ess, MD, PhD

      Affiliations

    • Departments of Neurology and Pediatrics, Washington University School of Medicine, St Louis, MO
    • Division of Pediatric and Developmental Neurology and the Pediatric Epilepsy Center, Tuberous Sclerosis Clinic, St Louis Children’s Hospital, St Louis, MO.
    • Corresponding Author InformationAddress reprint requests to Kevin C. Ess, MD, PhD, Vanderbilt University, Department of Neurology, 2311 Pierce Avenue, Nashville, TN 37232-3375.

References 

  1. Mizuguchi MTS . Neuropathology of tuberous sclerosis . Brain Dev . 2001;23:508–515
  2. Astrinidis A , Henske EP . Aberrant cellular differentiation and migration in renal and pulmonary tuberous sclerosis complex . J Child Neurol . 2004;19:710–715
  3. Papakonstantinou E , Dionyssopoulos A , Pesintzaki C , et al.   Expression of proteoglycans and glycosaminoglycans in angiofibroma and fibrous plaque skin lesions from patients with tuberous sclerosis . Arch Dermatol Res . 2003;295:138–145
  4. Medioni D , Pages A , Sarda P . Natural history of cardiac rhabdomyoma Presentation of 2 cases with immunohistochemical study and review of the literature . Arch Anat Cytol Pathol . 1994;42:29–34
  5. Crino PB , Henske EP . New developments in the neurobiology of the tuberous sclerosis complex . Neurology . 1999;53:1384–1390
  6. Chiron C , Dumas C , Jambaque I , et al.   Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis . Epilepsy Res . 1997;26:389–395
  7. Elterman RD , Shields WD , Mansfield KA , et al.   Randomized trial of vigabatrin in patients with infantile spasms . Neurology . 2001;57:1416–1421
  8. Spencer EL , Harding GF . Examining visual field defects in the paediatric population exposed to vigabatrin . Doc Ophthalmol . 2003;107:281–287
  9. Best JL , Acheson JF . The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication . Eye . 2005;19:41–44
  10. Franz DN , Tudor C , Leonard J , et al.   Lamotrigine therapy of epilepsy in tuberous sclerosis . Epilepsia . 2001;42:935–940
  11. Wong M , Ess KC , Uhlmann EJ , et al.   Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model . Ann Neurol . 2003;54:251–256
  12. Wiznitzer M . Autism and tuberous sclerosis . J Child Neurol . 2004;19:675–679
  13. Roach ES , Gomez MR , Northrup H . Tuberous sclerosis complex consensus conference (revised clinical diagnostic criteria) . J Child Neurol . 1998;13:624–628
  14. Hyman MH , Whittemore VH . National Institutes of Health consensus conference (tuberous sclerosis complex) . Arch Neurol . 2000;57:662–665
  15. Goodman M , Lamm SH , Engel A , et al.   Cortical tuber count (a biomarker indicating neurologic severity of tuberous sclerosis complex) . J Child Neurol . 1997;12:85–90
  16. Shepherd CW , Houser OW , Gomez MR . MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment . AJNR Am J Neuroradiol . 1995;16:149–155
  17. Bolton PF , Griffiths PD . Association of tuberous sclerosis of temporal lobes with autism and atypical autism . Lancet . 1997;349:392–395
  18. Bolton PF , Park RJ , Higgins JN , et al.   Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex . Brain . 2002;125:1247–1255
  19. Baker P , Piven J , Sato Y . Autism and tuberous sclerosis complex (prevalence and clinical features) . J Autism Dev Disord . 1998;28:279–285
  20. Lee A , Maldonado M , Baybis M , et al.   Markers of cellular proliferation are expressed in cortical tubers . Ann Neurol . 2003;53:668–673
  21. Ess K , Uhlmann EJ , Li W , et al.   Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology . Glia . 2004;46:28–40
  22. Park SH , Pepkowitz SH , Kerfoot C , et al.   Tuberous sclerosis in a 20-week gestation fetus (immunohistochemical study) . Acta Neuropathol (Berl) . 1997;94:180–186
  23. Baron Y , Barkovich AJ . MR imaging of tuberous sclerosis in neonates and young infants . AJNR Am J Neuroradiol . 1999;20:907–916
  24. Goh S , Butler W , Thiele EA . Subependymal giant cell tumors in tuberous sclerosis complex . Neurology . 2004;63:1457–1461
  25. Ess KC , Kamp CA , Tu BP , et al.   Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex . Neurology . 2005;64:1446–1449
  26. Hirose T , Scheithauer BW , Lopes MB , et al.   Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis (an immunohistochemical, ultrastructural, and immunoelectron and microscopic study) . Acta Neuropathol (Berl) . 1995;90:387–399
  27. Dickerson WW . Familial occurrence of tuberous sclerosis . AMA Arch Neurol Psychiatry . 1951;65:683–702
  28. Fryer AE , Chalmers A , Connor JM , et al.   Evidence that the gene for tuberous sclerosis is on chromosome 9 . Lancet . 1987;1:659–661
  29. Kandt RS , Haines JL , Smith M , et al.   Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease . Nat Genet . 1992;2:37–41
  30. Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16 . Cell . 1993;75:1305–1315
  31. van Slegtenhorst M , de Hoogt R , Hermans C , et al.   Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 . Science . 1997;277:805–808
  32. Jones AC , Shyamsundar MM , Thomas MW , et al.   Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis . Am J Hum Genet . 1999;64:1305–1315
  33. Dabora SL , Jozwiak S , Franz DN , et al.   Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs . Am J Hum Genet . 2001;68:64–80
  34. Sancak O , Nellist M , Goedbloed M , et al.   Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting (genotype–phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex) . Eur J Hum Genet . 2005;13:731–741
  35. Au KS , Hebert AA , Roach ES , et al.   Complete inactivation of the TSC2 gene leads to formation of hamartomas . Am J Hum Genet . 1999;65:1790–1795
  36. Niida Y , Stemmer-Rachamimov AO , Logrip M , et al.   Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions . Am J Hum Genet . 2001;69:493–503
  37. Ma L , Chen Z , Erdjument-Bromage H , et al.   Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis . Cell . 2005;121:179–193
  38. Johnson MW , Kerfoot C , Bushnell T , et al.   Hamartin and tuberin expression in human tissues . Mod Pathol . 2001;14:202–210
  39. Murthy V , Stemmer-Rachamimov AO , Haddad LA , et al.   Developmental expression of the tuberous sclerosis proteins tuberin and hamartin . Acta Neuropathol . 2001;101:202–210
  40. Kerfoot C , Wienecke R , Menchine M , et al.   Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis . Brain Pathol . 1996;6:367–375
  41. Geist RT , Reddy AJ , Zhang J , et al.   Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues . Neurobiol Dis . 1996;3:111–120
  42. Gutmann DH , Zhang Y , Hasbani MJ , et al.   Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues . Acta Neuropathol . 2000;99:223–230
  43. Catania MG , Johnson MW , Liau LM , et al.   Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures . J Neurosci Res . 2001;63:276–283
  44. Plank TL , Yeung RS , Henske EP . Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles . Cancer Res . 1998;58:4766–4770
  45. van Slegtenhorst M , Nellist M , Nagelkerken B , et al.   Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products . Hum Mol Genet . 1998;7:1053–1057
  46. Miloloza A , Rosner M , Nellist M , et al.   The TSC1 gene product, hamartin, negatively regulates cell proliferation . Hum Mol Genet . 2000;9:1721–1727
  47. Jin F , Wienecke R , Xiao GH , et al.   Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region . Proc Natl Acad Sci U S A . 1996;93:9154–9159
  48. Tapon N , Ito N , Dickson BJ , et al.   The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation . Cell . 2001;105:345–355
  49. Hodges AK , Li S , Maynard J , et al.   Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin . Hum Mol Genet . 2001;10:2899–2905
  50. Benvenuto G , Li S , Brown SJ , et al.   The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination . Oncogene . 2000;19:6306–6316
  51. Lamb RF , Roy C , Diefenbach TJ , et al.   The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho . Nat Cell Biol . 2000;2:281–287
  52. Haddad LA , Smith N , Bowser M , et al.   The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton . J Biol Chem . 2002;277:44180–44186
  53. Kwiatkowski DJ . Rhebbing up mTOR (new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis) . Cancer Biol Ther . 2003;2:471–476
  54. Mak BC , Yeung RS . The tuberous sclerosis complex genes in tumor development . Cancer Invest . 2004;22:588–603
  55. Inoki K , Corradetti MN , Guan KL . Dysregulation of the TSC-mTOR pathway in human disease . Nat Genet . 2005;37:19–24
  56. Findlay GM , Harrington LS , Lamb RF . TSC1-2 tumour suppressor and regulation of mTOR signalling (linking cell growth and proliferation?) . Curr Opin Genet Dev . 2005;15:69–76
  57. Potter CJ , Huang H , Xu T . Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size . Cell . 2001;105:357–368
  58. Ito N , Rubin GM . gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle . Cell . 1999;96:529–539
  59. Dan HC , Sun M , Yang L , et al.   Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin . J Biol Chem . 2002;277:35364–35370
  60. Manning BD , Tee AR , Logsdon MN , et al.   Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway . Mol Cell . 2002;10:151–162
  61. Krymskaya VP . Tumour suppressors hamartin and tuberin (intracellular signalling) . Cell Signal . 2003;15:729–739
  62. Gao X , Neufeld TP , Pan D . Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways . Dev Biol . 2000;221:404–418
  63. Inoki K , Zhu T , Guan KL . TSC2 mediates cellular energy response to control cell growth and survival . Cell . 2003;115:577–590
  64. Corradetti MN , Inoki K , Bardeesy N , et al.   Regulation of the TSC pathway by LKB1 (evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome) . Genes Dev . 2004;18:1533–1538
  65. Nelen MR , van Staveren WC , Peeters EA , et al.   Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet . 1997;6:1383–1387
  66. Liaw D , Marsh DJ , Li J , et al.   Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome . Nat Genet . 1997;16:64–67
  67. Marsh DJ , Roth S , Lunetta KL , et al.   Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome . Cancer Res . 1997;57:5017–5021
  68. Bonneau D , Longy M . Mutations of the human PTEN gene . Hum Mutat . 2000;16:109–122
  69. Hemminki A , Markie D , Tomlinson I , et al.   A serine/threonine kinase gene defective in Peutz-Jeghers syndrome . Nature . 1998;391:184–187
  70. Launonen V . Mutations in the human LKB1/STK11 gene . Hum Mutat . 2005;26:291–297
  71. Gao X , Pan D . TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth . Genes Dev . 2001;15:1383–1392
  72. Jaeschke A , Hartkamp J , Saitoh M , et al.   Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent . J Cell Biol . 2002;159:217–224
  73. Kwiatkowski DJ , Zhang H , Bandura JL , et al.   A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells . Hum Mol Genet . 2002;11:525–534
  74. Pende M , Um SH , Mieulet V , et al.   S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway . Mol Cell Biol . 2004;24:3112–3124
  75. Holland EC , Sonenberg N , Pandolfi PP , et al.   Signaling control of mRNA translation in cancer pathogenesis . Oncogene . 2004;23:3138–3144
  76. Yamagata K , Sanders LK , Kaufmann WE , et al.   rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein . J Biol Chem . 1994;269:16333–16339
  77. Inoki K , Li Y , Xu T , et al.   Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling . Genes Dev . 2003;17:1829–1834
  78. Uhlmann EJ , Li W , Scheidenhelm DK , et al.   Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation . Glia . 2004;47:180–188
  79. Inoki K , Li Y , Zhu T , et al.   TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling . Nat Cell Biol . 2002;4:648–657
  80. Garami A , Zwartkruis FJ , Nobukuni T , et al.   Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 . Mol Cell . 2003;11:1457–1466
  81. Castro AF , Rebhun JF , Clark GJ , et al.   Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner . J Biol Chem . 2003;278:32493–32496
  82. Long X , Lin Y , Ortiz-Vega S , et al.   Rheb binds and regulates the mTOR kinase . Curr Biol . 2005;15:702–713
  83. Kobayashi T , Minowa O , Kuno J , et al.   Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice . Cancer Res . 1999;59:1206–1211
  84. Onda H , Lueck A , Marks PW , et al.   Tsc2(+/−) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background . J Clin Invest . 1999;104:687–695
  85. Kobayashi T , Minowa O , Sugitani Y , et al.   A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice . Proc Natl Acad Sci U S A . 2001;98:8762–8767
  86. Uhlmann EJ , Apicelli AJ , Baldwin RL , et al.   Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/− cells . Oncogene . 2002;21:4050–4059
  87. Eker R . Familial renal adenomas in Wistar rats (a preliminary report) . Acta Pathol Microbiol Scand . 1954;34:554–562
  88. Kobayashi T , Hirayama Y , Kobayashi E , et al.   A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer . Nat Genet . 1995;9:70–74
  89. Mizuguchi M , Takashima S , Yamanouchi H , et al.   Novel cerebral lesions in the Eker rat model of tuberous sclerosis (cortical tuber and anaplastic ganglioglioma) . J Neuropathol Exp Neurol . 2000;59:188–196
  90. Uhlmann EJ , Wong M , Baldwin RL , et al.   Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures . Ann Neurol . 2002;52:285–296

PII: S1071-9091(06)00013-1

doi: 10.1016/j.spen.2006.01.009

Seminars in Pediatric Neurology
Volume 13, Issue 1 , Pages 37-42 , March 2006

Article Tools

* Image Usage & Resolution